

Michael D Wiese

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3954484/michael-d-wiese-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

130
papers

3,359
citations

30
h-index

54
g-index

138
ext. papers

4,031
ext. citations

4.2
avg, IF

5.49
L-index

#	Paper	IF	Citations
130	Population Pharmacokinetic Model for Tramadol and O-desmethyltramadol in Older Patients.. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2022 , 1	2.7	
129	Association between Patient-Reported Outcomes and Survival in Patients with Advanced Urothelial Carcinoma Treated with Atezolizumab. <i>Bladder Cancer</i> , 2022 , 8, 81-88	1	2
128	Maternal-placental-fetal drug metabolism is altered by late gestation undernutrition in the pregnant ewe.. <i>Life Sciences</i> , 2022 , 298, 120521	6.8	0
127	Precision Medicine With Leflunomide: Consideration of the DHODH Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021 , 73, 983-989	4.7	4
126	Intrauterine growth restriction alters the activity of drug metabolising enzymes in the maternal-placental-fetal unit. <i>Life Sciences</i> , 2021 , 285, 120016	6.8	2
125	The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data. <i>Npj Breast Cancer</i> , 2021 , 7, 30	7.8	6
124	Population pharmacokinetic model of subcutaneous fentanyl in older acute care patients. <i>European Journal of Clinical Pharmacology</i> , 2021 , 77, 1357-1368	2.8	1
123	LC-MS/MS analysis of vitamin D metabolites in human serum using a salting-out based liquid-liquid extraction and DAPTAD derivatization. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021 , 1173, 122654	3.2	4
122	Global View on Ant Venom Allergy: from Allergenic Components to Clinical Management. <i>Clinical Reviews in Allergy and Immunology</i> , 2021 , 1	12.3	0
121	Efficacy and safety of statins in ethnic differences: a lesson for application in Indigenous Australian patient care. <i>Pharmacogenomics</i> , 2021 , 22, 553-571	2.6	
120	The efficacy of systemic administration of lipopolysaccharide in modelling pre-motor Parkinson@ disease in C57BL/6 mice. <i>NeuroToxicology</i> , 2021 , 85, 254-264	4.4	3
119	Alterations in drug disposition in older adults: a focus on geriatric syndromes. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021 , 17, 41-52	5.5	16
118	Opioid prescribing and risk of drug-opioid interactions in older discharged patients with polypharmacy in Australia. <i>International Journal of Clinical Pharmacy</i> , 2021 , 43, 365-374	2.3	2
117	COVID-19: can we treat the mother without harming her baby?. <i>Journal of Developmental Origins of Health and Disease</i> , 2021 , 1-11	2.4	2
116	Concomitant beta-blocker use is associated with a reduced rate of remission in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs: a multicohort analysis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021 , 13, 1759720X211009020	3.8	1
115	Impact of resveratrol-mediated increase in uterine artery blood flow on fetal haemodynamics, blood pressure and oxygenation in sheep. <i>Experimental Physiology</i> , 2021 , 106, 1166-1180	2.4	2
114	Simultaneous LC-MS/MS quantification of oxycodone, tramadol and fentanyl and their metabolites (noroxycodone, oxymorphone, O- desmethyltramadol, N- desmethyltramadol, and norfentanyl) in human plasma and whole blood collected via venepuncture and volumetric absorptive micro sampling. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021 , 203, 1144174	3.5	3

113	Redox ratio in the left ventricle of the growth restricted fetus is positively correlated with cardiac output. <i>Journal of Biophotonics</i> , 2021 , 14, e202100157	3.1	1
112	Impact of maternal late gestation undernutrition on surfactant maturation, pulmonary blood flow and oxygen delivery measured by magnetic resonance imaging in the sheep fetus. <i>Journal of Physiology</i> , 2021 , 599, 4705-4724	3.9	1
111	A review of liquid biopsy as a tool to assess epigenetic, cfDNA and miRNA variability as methotrexate response predictors in patients with rheumatoid arthritis. <i>Pharmacological Research</i> , 2021 , 173, 105887	10.2	4
110	Hepatic cytochrome P450 function is reduced by life-long Western diet consumption in guinea pig independent of birth weight. <i>Life Sciences</i> , 2021 , 287, 120133	6.8	1
109	Methamphetamine administration increases hepatic CYP1A2 but not CYP3A4 activity in female guinea pigs. <i>PLoS ONE</i> , 2020 , 15, e0233010	3.7	5
108	Fetal cardiovascular response to acute hypoxia during maternal anesthesia. <i>Physiological Reports</i> , 2020 , 8, e14365	2.6	5
107	A literature review of treatment-specific clinical prediction models in patients with breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 148, 102908	7	7
106	Prevalence and Factors Associated with Analgesic Prescribing in Poly-Medicated Elderly Patients. <i>Drugs and Aging</i> , 2020 , 37, 291-300	4.7	6
105	Investigational IRAK-4 inhibitors for the treatment of rheumatoid arthritis. <i>Expert Opinion on Investigational Drugs</i> , 2020 , 29, 475-482	5.9	16
104	Predicting Thrombocytopenia in Patients With Breast Cancer Treated With Ado-trastuzumab Emtansine. <i>Clinical Breast Cancer</i> , 2020 , 20, e220-e228	3	5
103	Repeat serological testing for anti-citrullinated peptide antibody after commencement of therapy is not helpful in patients with seronegative rheumatoid arthritis. <i>Internal Medicine Journal</i> , 2020 , 50, 818-822	1.6	1
102	The Influence of Pre-Existing Beta-Blockers Use on Survival Outcomes in HER2 Positive Advanced Breast Cancer: Pooled Analysis of Clinical Trial Data. <i>Frontiers in Oncology</i> , 2020 , 10, 1130	5.3	3
101	The impact of intrauterine growth restriction on cytochrome P450 enzyme expression and activity. <i>Placenta</i> , 2020 , 99, 50-62	3.4	1
100	Development of a method to determine cytochrome P450 1A2, 2C9, 2D6 and 3A4 activity sheep hepatic microsomes. <i>Journal of Pharmacological and Toxicological Methods</i> , 2020 , 106, 106934	1.7	4
99	Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs. <i>Scientific Reports</i> , 2020 , 10, 18634	4.9	3
98	Nuances to precision dosing strategies of targeted cancer medicines. <i>Pharmacology Research and Perspectives</i> , 2020 , 8, e00625	3.1	3
97	Factors associated with medication adherence in a longitudinal study of rheumatoid arthritis patients. <i>International Journal of Clinical Practice</i> , 2019 , 73, e13375	2.9	8
96	Pharmaceutical and preclinical evaluation of Advax adjuvant as a dose-sparing strategy for ant venom immunotherapy. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019 , 172, 1-8	3.5	4

95	Considerations in selecting postoperative analgesia for pregnant sheep following fetal instrumentation surgery. <i>Animal Frontiers</i> , 2019 , 9, 60-67	5.5	19
94	Subcutaneous maternal resveratrol treatment increases uterine artery blood flow in the pregnant ewe and increases fetal but not cardiac growth. <i>Journal of Physiology</i> , 2019 , 597, 5063-5077	3.9	13
93	Does poor fetal growth influence the extent of fetal exposure to maternal medications?. <i>Pharmacological Research</i> , 2018 , 130, 74-84	10.2	8
92	Towards complete identification of allergens in Jack Jumper (<i>Myrmecia pilosula</i>) ant venom and their clinical relevance: An immunoproteomic approach. <i>Clinical and Experimental Allergy</i> , 2018 , 48, 1222-1234	4.1	8
91	Intrauterine growth restriction may reduce hepatic drug metabolism in the early neonatal period. <i>Pharmacological Research</i> , 2018 , 134, 68-78	10.2	10
90	Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 462-476	3.8	40
89	Genetic polymorphism of the methotrexate transporter ABCG2, blood pressure and markers of arterial function in patients with rheumatoid arthritis: repeated cross-sectional study. <i>Pharmacogenomics and Personalized Medicine</i> , 2018 , 11, 205-210	2.1	4
88	The PTPN22 gene is associated with idiopathic inflammatory myopathy. <i>Muscle and Nerve</i> , 2017 , 55, 270-273	3.7	2
87	Adherence to combination DMARD therapy and treatment outcomes in rheumatoid arthritis: a longitudinal study of new and existing DMARD users. <i>Rheumatology International</i> , 2017 , 37, 897-904	3.6	16
86	The Routine Clinical use of Pharmacogenetic Tests: What it Will Require?. <i>Pharmaceutical Research</i> , 2017 , 34, 1544-1550	4.5	13
85	Infliximab Maintenance Dosing in Inflammatory Bowel Disease: an Example for In Silico Assessment of Adaptive Dosing Strategies. <i>AAPS Journal</i> , 2017 , 19, 1136-1147	3.7	19
84	Putting recommendations into practice: Australian rheumatologists' opinions on leflunomide use in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2017 , 36, 791-798	3.9	2
83	Clinical Outcomes Associated with Medication Regimen Complexity in Older People: A Systematic Review. <i>Journal of the American Geriatrics Society</i> , 2017 , 65, 747-753	5.6	90
82	Determining the acceptable level of physician compliance with a treat-to-target strategy in early rheumatoid arthritis. <i>International Journal of Rheumatic Diseases</i> , 2017 , 20, 576-583	2.3	6
81	Methotrexate, blood pressure and markers of arterial function in patients with rheumatoid arthritis: a repeated cross-sectional study. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2017 , 9, 213-229	3.8	16
80	Disease activity trajectories in early rheumatoid arthritis following intensive DMARD therapy over 3 years: association with persistence to therapy. <i>International Journal of Rheumatic Diseases</i> , 2017 , 20, 1447-1456	2.3	6
79	Improving community access to terminal phase medicines in Australia: identification of the key considerations for the implementation of a core medicines list. <i>Australian Journal of Primary Health</i> , 2017 , 23, 373-378	1.4	2
78	Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers. <i>British Journal of Cancer</i> , 2017 , 117, 913-920	8.7	111

77	Factors influencing the quality of <i>Myrmecia pilosula</i> (Jack Jumper) ant venom for use in in vitro and in vivo diagnoses of allergen sensitization and in allergen immunotherapy. <i>Clinical and Experimental Allergy</i> , 2017 , 47, 1478-1490	4.1	4
76	Intracellular CD3+ T Lymphocyte Teriflunomide Concentration Is Poorly Correlated with and Has Greater Variability Than Unbound Plasma Teriflunomide Concentration. <i>Drug Metabolism and Disposition</i> , 2017 , 45, 8-16	4	7
75	Changes to the Australian Pharmaceutical Benefit Scheme restrictions for biological disease-modifying antirheumatic drugs have influenced the use of leflunomide. <i>International Journal of Rheumatic Diseases</i> , 2017 , 20, 1795-1797	2.3	1
74	Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017 , 13, 31-45	5.5	37
73	Treating rheumatoid arthritis to target: physician and patient adherence issues in contemporary rheumatoid arthritis therapy. <i>Journal of Evaluation in Clinical Practice</i> , 2017 , 23, 486-493	2.5	10
72	Effect of Adherence to Protocolized Targeted Intensifications of Disease-modifying Antirheumatic Drugs on Treatment Outcomes in Rheumatoid Arthritis: Results from an Australian Early Arthritis Cohort. <i>Journal of Rheumatology</i> , 2016 , 43, 1643-9	4.1	8
71	Pharmacogenetic and ethnicity influence on oxaliplatin therapy for colorectal cancer: a meta-analysis. <i>Pharmacogenomics</i> , 2016 , 17, 1725-1732	2.6	10
70	Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours. <i>European Journal of Cancer</i> , 2016 , 55, 122-30	7.5	26
69	Medication Regimen Complexity and Polypharmacy as Factors Associated With All-Cause Mortality in Older People: A Population-Based Cohort Study. <i>Annals of Pharmacotherapy</i> , 2016 , 50, 89-95	2.9	70
68	Medication Regimen Complexity and Number of Medications as Factors Associated With Unplanned Hospitalizations in Older People: A Population-based Cohort Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2016 , 71, 831-7	6.4	50
67	Targeted pharmacotherapy after somatic cancer mutation screening. <i>F1000Research</i> , 2016 , 5, 1551	3.6	7
66	Targeted pharmacotherapy after somatic cancer mutation screening. <i>F1000Research</i> , 2016 , 5, 1551	3.6	4
65	Ten years of publicly funded biological disease-modifying antirheumatic drugs in Australia. <i>Medical Journal of Australia</i> , 2016 , 204, 64-8	4	11
64	A model-based evaluation of single metrics for discriminating changes in rheumatoid arthritis disease activity. <i>British Journal of Clinical Pharmacology</i> , 2016 , 81, 1046-57	3.8	1
63	Extended boiling of peanut progressively reduces IgE allergenicity while retaining T cell reactivity. <i>Clinical and Experimental Allergy</i> , 2016 , 46, 1004-14	4.1	25
62	Drug-induced toxicity and patient reported outcomes in rheumatoid arthritis patients following intensive treated-to-target strategy: does ceasing therapy due to toxicity worsen outcomes in long term?. <i>International Journal of Clinical Practice</i> , 2016 , 70, 340-50	2.9	2
61	PTPN22 R620W minor allele is a genetic risk factor for giant cell arteritis. <i>RMD Open</i> , 2016 , 2, e000246	5.9	6
60	Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis. <i>British Journal of Clinical Pharmacology</i> , 2016 , 81, 113-23	3.8	17

59	The role and utility of measuring red blood cell methotrexate polyglutamate concentrations in inflammatory arthropathies--a systematic review. <i>European Journal of Clinical Pharmacology</i> , 2015 , 71, 411-23	2.8	11
58	Pilosulins: a review of the structure and mode of action of venom peptides from an Australian ant <i>Myrmecia pilosula</i> . <i>Toxicon</i> , 2015 , 98, 54-61	2.8	27
57	Factors associated with medication regimen complexity in older people: a cross-sectional population-based study. <i>European Journal of Clinical Pharmacology</i> , 2015 , 71, 1099-108	2.8	30
56	A population model of early rheumatoid arthritis disease activity during treatment with methotrexate, sulfasalazine and hydroxychloroquine. <i>British Journal of Clinical Pharmacology</i> , 2015 , 79, 777-88	3.8	4
55	Characterising deviation from treat-to-target strategies for early rheumatoid arthritis: the first three years. <i>Arthritis Research and Therapy</i> , 2015 , 17, 48	5.7	18
54	Reply: Comment on QMeta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancerQ <i>British Journal of Cancer</i> , 2015 , 113, 1635	8.7	6
53	Feasibility of a patient-centered deprescribing process to reduce inappropriate use of proton pump inhibitors. <i>Annals of Pharmacotherapy</i> , 2015 , 49, 29-38	2.9	55
52	Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. <i>Annals of Oncology</i> , 2015 , 26, 13-21	10.3	351
51	Response to Physiologically Based Pharmacokinetic Model for Prediction of Leflunomide and Teriflunomide-Should Consideration Be Given to Cannalicular Efflux Transporters?. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015 , 4, 564	4.5	
50	Semiphysiologically Based Pharmacokinetic Model of Leflunomide Disposition in Rheumatoid Arthritis Patients. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015 , 4, 362-71	4.5	12
49	Pharmacists in Australian general practice: an opportunity for expertise in precision medicine. <i>Therapeutic Advances in Drug Safety</i> , 2015 , 6, 186-8	3.5	7
48	Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2015 , 112, 1888-94	8.7	223
47	Alterations in drug disposition in older adults. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015 , 11, 491-508	5.5	64
46	BRAF V600E and survival benefit of anti-EGFR monoclonal antibody (mAb) therapy for metastatic colorectal cancer (mCRC): A meta-analysis.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e14605-e14605	2.2	
45	The rheumatoid arthritis susceptibility polymorphism PTPN22 C1858T is not associated with leflunomide response or toxicity. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2014 , 39, 555-60	2.2	7
44	Metabolic and safety issues for multiple sclerosis pharmacotherapy--opportunities for personalised medicine. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014 , 10, 1145-59	5.5	3
43	Immediate-type hypersensitivity drug reactions. <i>British Journal of Clinical Pharmacology</i> , 2014 , 78, 1-13	3.8	31
42	Polypharmacy and medication regimen complexity as factors associated with hospital discharge destination among older people: a prospective cohort study. <i>Drugs and Aging</i> , 2014 , 31, 623-30	4.7	31

41	Medication Regimen Complexity and Unplanned Hospital Readmissions in Older People. <i>Annals of Pharmacotherapy</i> , 2014 , 48, 1120-1128	2.9	51
40	Systemic allergy to EDTA in local anesthetic and radiocontrast media. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2014 , 2, 225-9	5.4	18
39	The benefits and harms of deprescribing. <i>Medical Journal of Australia</i> , 2014 , 201, 386-9	4	60
38	CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis. <i>Circulation: Cardiovascular Genetics</i> , 2014 , 7, 895-902		77
37	Pharmacogenomic substudies of randomized controlled trials: consideration of safety outcomes. <i>Therapeutic Advances in Drug Safety</i> , 2014 , 5, 62-6	3.5	8
36	Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis. <i>Pharmacogenomics Journal</i> , 2014 , 14, 350-5	3.5	23
35	Review of deprescribing processes and development of an evidence-based, patient-centred deprescribing process. <i>British Journal of Clinical Pharmacology</i> , 2014 , 78, 738-47	3.8	162
34	Individualization of leflunomide dosing in rheumatoid arthritis patients. <i>Personalized Medicine</i> , 2014 , 11, 449-461	2.2	5
33	Benefits of deprescribing on patients' adherence to medications. <i>International Journal of Clinical Pharmacy</i> , 2014 , 36, 26-9	2.3	61
32	Development and validation of the patients' attitudes towards deprescribing (PATD) questionnaire. <i>International Journal of Clinical Pharmacy</i> , 2013 , 35, 51-6	2.3	63
31	Patient barriers to and enablers of deprescribing: a systematic review. <i>Drugs and Aging</i> , 2013 , 30, 793-807	4.7	268
30	Review of the cost effectiveness of pharmacogenetic-guided treatment of hypercholesterolaemia. <i>Pharmacoeconomics</i> , 2013 , 31, 377-91	4.4	13
29	Leflunomide for inflammatory arthritis in end-stage renal disease on peritoneal dialysis: a pharmacokinetic and pharmacogenetic study. <i>Annals of Pharmacotherapy</i> , 2013 , 47, e15	2.9	7
28	Predicted metabolic drug clearance with increasing adult age. <i>British Journal of Clinical Pharmacology</i> , 2013 , 75, 1019-28	3.8	38
27	Challenges and limitations in the interpretation of systematic reviews: making sense of clopidogrel and CYP2C19 pharmacogenetics. <i>Clinical Pharmacology and Therapeutics</i> , 2013 , 94, 376-82	6.1	19
26	Cost-effectiveness of using CYP2C19 genotype to guide selection of clopidogrel or ticagrelor in Australia. <i>Pharmacogenomics</i> , 2013 , 14, 2013-21	2.6	23
25	The validity of sequence symmetry analysis (SSA) for adverse drug reaction signal detection. <i>Pharmacoepidemiology and Drug Safety</i> , 2013 , 22, 496-502	2.6	47
24	People's attitudes, beliefs, and experiences regarding polypharmacy and willingness to Deprescribe. <i>Journal of the American Geriatrics Society</i> , 2013 , 61, 1508-14	5.6	139

23	Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013 , 9, 1025-35	5.5	32
22	Oral drug challenges in non-steroidal anti-inflammatory drug-induced urticaria, angioedema and anaphylaxis. <i>Internal Medicine Journal</i> , 2012 , 42, 665-71	1.6	29
21	Adherence to medication for the treatment of psychosis: rates and risk factors in an Ethiopian population. <i>BMC Clinical Pharmacology</i> , 2012 , 12, 10		14
20	Ultrarush versus semirush initiation of insect venom immunotherapy: a randomized controlled trial. <i>Journal of Allergy and Clinical Immunology</i> , 2012 , 130, 162-8	11.5	36
19	Difficulties reducing inappropriate prescribing of proton pump inhibitors in the elderly. <i>Drugs and Aging</i> , 2012 , 29, 925-6; author reply 927-8	4.7	4
18	Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2012 , 14, R163	5.7	37
17	Perceived and actual paracetamol dosing in overweight and obese children. <i>European Journal of Hospital Pharmacy</i> , 2012 , 19, 438-442	1.6	3
16	Systematic review and meta-analysis of the association between cytochrome P450 2C19 genotype and bleeding. <i>Thrombosis and Haemostasis</i> , 2012 , 108, 199-200	7	17
15	Association of DHODH haplotype variants and response to leflunomide treatment in rheumatoid arthritis. <i>Pharmacogenomics</i> , 2012 , 13, 1427-34	2.6	22
14	Causes of ant sting anaphylaxis in Australia: the Australian Ant Venom Allergy Study. <i>Medical Journal of Australia</i> , 2011 , 195, 69-73	4	27
13	Using time-resolved fluorescence to measure serum venom-specific IgE and IgG. <i>PLoS ONE</i> , 2011 , 6, e16741	3.4	8
12	Stability of <i>Myrmecia pilosula</i> (Jack Jumper) Ant venom for use in immunotherapy. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2011 , 54, 303-10	3.5	10
11	Quantitation of total and free teriflunomide (A77 1726) in human plasma by LC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2011 , 55, 325-31	3.5	30
10	Pilosulin 5, a novel histamine-releasing peptide of the Australian ant, <i>Myrmecia pilosula</i> (Jack Jumper Ant). <i>Archives of Biochemistry and Biophysics</i> , 2008 , 477, 411-6	4.1	28
9	<i>Myrmecia pilosula</i> (Jack Jumper) ant venom: validation of a procedure to standardise an allergy vaccine. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2008 , 46, 58-65	3.5	15
8	<i>Myrmecia pilosula</i> (Jack Jumper) ant venom: identification of allergens and revised nomenclature. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2007 , 62, 437-43	9.3	35
7	Proteomic analysis of <i>Myrmecia pilosula</i> (jack jumper) ant venom. <i>Toxicon</i> , 2006 , 47, 208-17	2.8	37
6	Efficacy of ant venom immunotherapy and whole body extracts. <i>Journal of Allergy and Clinical Immunology</i> , 2005 , 116, 464-5; author reply 465-6	11.5	4

5	Characterisation of major peptides in Black jumper ant venom by mass spectrometry. <i>Toxicon</i> , 2004 , 43, 173-83	2.8	49
4	Ant venom immunotherapy: a double-blind, placebo-controlled, crossover trial. <i>Lancet, The</i> , 2003 , 361, 1001-6	4.0	109
3	Raised INR with Concurrent Warfarin and Azithromycin. <i>Journal of Pharmacy Practice and Research</i> , 1999 , 29, 159-161		6
2	Unexpected Orthostatic Hypotension with Venlafaxine. <i>Journal of Pharmacy Practice and Research</i> , 1999 , 29, 215-216		2
1	The effect of angiotensin II receptor antagonist on the exogenous erythropoietin requirement of haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 1999 , 14, 2047-2049	4.3	18